Phase 1 N=78 Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
Atopic Dermatitis · Healthy Volunteers
Primary: Number of Participants With Adverse Events — 3; 5; 1; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Smoking Cessation Pilot for People Living With HIV (PLWH)
Smoking Cessation · Smoking · Smoking Behaviors
Primary: Percentage of Participants With Biochemically Verified 7-day Point Prevalence Smoking/Tobacco Abstinence — 15.0; 11.8 percentage of participants — p=0.77
Phase 2 N=56 Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Follicular Lymphoma · Non-Hodgkin's Lymphoma Follicular · Non-Hodgkin's Lymphoma, Adult High Grade
Primary: Complete Response (CR) at End of Induction — 41; 11; 1; 0 Participants
N/A N=60 Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study
Perinatal Depression · Postpartum Depression · Depression
Primary: Change in Depressive Symptoms — 6.5; 9.7; 4.5; 8.4 score on a scale — p=<0.05
Phase 3 N=1,018 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
Ebola Virus Disease
Primary: Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8) — 12; 51; 17; 14 Participants
Phase 2 N=28 A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Change From Baseline in DAS-28 (CRP) at Week 6 — -1.29; -1.24 Score on a scale — p=0.885
Phase 4 N=11 Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia
Postoperative Nausea
Primary: Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Upper Extremity) — 2.685; 2.545; 2.58; 2.292 µV — p=0.35
N/A N=32 Manual Ventilation Efficacy With MVG Device
Ventilator Lung
Primary: Tidal Volume — 502.030; 492.508; 478.889; 481.533 mL
Phase 1 N=21 Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone
Healthy Subjects · Opioid Antagonist · Pharmacokinetics
Primary: First Timepoint When There is a Higher Naloxone Plasma Concentration in the 4 Naloxone Dose Arm (1 Every 2.5 Min) Compared to the 2 Naloxone Dose Arm (1 Every 2.5 Min)…
Phase 2 N=1,242 A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
Arthroplasty, Replacement, Knee
Primary: Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated) — 7; 30; 27; 14 Participants
Phase 2 N=40 Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients
Hypercholesterolemia · Dyslipidemias
Primary: Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-C — 9; 9; 1; 7 Participants
Phase 3 N=31 Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
Gaucher Disease
Primary: Number of Participants With Mobility Status Assessments at Study Baseline, Weeks 52, 104, 156 and 208 — 31; 0; 0; 0 Participants
N/A N=78 Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women
Smoking Cessation
Primary: Change in the Number of Cigarettes Smoked Per Day — 0; 0 cigarettes per day
Phase 2 N=47 A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
NASH - Nonalcoholic Steatohepatitis · Fibrosis, Liver · NAFLD - Nonalcoholic Fatty Liver Disease
Primary: Number of Safety and Tolerability Events of CRV431 Versus Placebo. — 4; 8; 3; 21 Number of treatment emergent AE
N/A N=88 Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)
Heart Failure, Diastolic · Obesity
Primary: Peak Exercise Oxygen Consumption (VO2) — 1609; 1653 ml/min — p=0.21